Previous 10 | Next 10 |
HOUSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that, as per ...
Salarius Pharmaceuticals ( NASDAQ: SLRX ) will effect a 1-for-25 reverse stock split at 5:00 p.m. time today. The reverse stock split is intended to enable the company to regain Nasdaq compliance with the $1.00 minimum closing bid price requirement. At the effective ti...
HOUSTON, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of new treatment options, today announced that it will effect a 1-for-25 reverse stock spli...
HOUSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of new treatment options, today announced that management will present at the 2022 Ladenbu...
The shares of nanocap biotech Salarius Pharmaceuticals, Inc. ( NASDAQ: SLRX ) gained ~12% in the pre-market trading Monday after the company issued a letter to shareholders outlining its latest updates on financials and clinical programs. As of Jun. 30, SLRX reports $2...
Salarius Pharma ( NASDAQ: SLRX ) said on Monday it had added Mayo Clinic to its open-label Phase 1/2 trial with seclidemstat in Ewing’s sarcoma and FET-rearranged sarcomas. Mayo Clinic locations in Rochester, Minnesota, and Jacksonville, Florida are support...
Expands Trial to 17 U.S. Sites and 25 Locations Initiation of All Anticipated U.S. Trial Sites Largely Completed HOUSTON, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company developing therapies for p...
The following slide deck was published by Salarius Pharmaceuticals, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Salarius Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation
Salarius Pharmaceuticals, Inc. (SLRX) Q2 2022 Earnings Conference Call August 8, 2022, 11:00 AM ET Company Participants Kim Golodetz - Senior Vice President, Principal, LHA Investor Relations David Arthur - Director and CEO Mark Rosenblum - Chief Financial Office...
Salarius Pharmaceuticals press release ( NASDAQ: SLRX ): Q2 GAAP EPS of -$0.09 beats by $0.01 . Cash and equivalents were $22.6 million as of June 30, 2022, compared with $29.2 million as of December 31, 2021 Shares -9% PM. For further details see: Sa...
News, Short Squeeze, Breakout and More Instantly...
Salarius Pharmaceuticals Inc. Company Name:
SLRX Stock Symbol:
NYSE Market:
Salarius Pharmaceuticals Inc. Website:
2024-06-17 09:02:04 ET Solar Acquisition Corp (SLRX) announced stock split at a ratio of 1-for-8 on 2024-06-17 ... Full story available on KlickAnalytics.com
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14 predominantly higher risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (C...
HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect...